Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

nt and obliged to notify the Company of transactions involving Bavarian Nordic securities is awarded 5,000 warrants under the abovementioned award of warrants.

The value of each warrant equals DKK 39 and is calculated on the Black-Scholes model with a risk-free interest rate of 2.5 per cent and on the historical volatility of the shares. The calculation is based on a market value of the share of DKK 103 per share.

The award of warrants will incur consequential amendments to the Articles of Association.

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more informati
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... agenda for Arrowhead’s 2010 Personalized Me...ke place on February 22-24, 2010 in Philadelphia, ...e will highlight key issues in forming partnership...riences. , Minneapolis, M...head’s 2010 Personalized Medicine Partnersh...
(Date:11/5/2009)... 5 The endangered black-footed fer... This rare carnivore feeds on prairie dogs. The...ften entire population die-offs in towns occur. T...emented a ferret breeding program and has been rel...y native habitat. Unfortunately, plague can sweep...
(Date:11/5/2009)... Nov. 5 ThermoGenesis Co...tive products for processing and storing adult ste...ter of fiscal 2010. ,, For the quarter ended Se... $5.2 million, a 15 percent increase over revenues...The Company said the key contributors to the growt...
(Date:11/5/2009)... BioSpecifics Technologie...any developing first-in-class collagenase-based pr...the third quarter ended September 30, 2009. ,,...is year, the FDA,s Arthritis Advisory Committee un...oval of XIAFLEX(TM) for the treatment of Dupuytren...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...on , , MOUNT LAUREL, N.J. March 23 The ninth a...he premier educational event in the field of basic..., sponsored by the American Society of Transplant ...ansplantation (AST), will occur from May 30 - June... Boston, MA. , , Controversial topics and impor...
...ticals, Inc. (Nasdaq: ARNA ) announced today it ...to $50 million from Azimuth Opportunity Ltd. Durin...ment, Arena may sell newly issued registered share...at a pre-negotiated discount to the market price. ...timing and amount of any sales of its stock, subje...
..., Inc. (CTI) (NASDAQ and MTA: CTIC) today announce... for the year ended December 31, 2008. This filing...CellTherapeutics.com , or on the Securities and Ex..., As required under NASDAQ Marketplace Rule 4350(b...uditor,s report included in the annual report on F...
Other Biology Technology:American Transplant Congress 2009 2Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million 2
(Date:11/5/2009)...esearchers at Yale University have developed synth...une response to HIV and HIV-infected cells, as wel...lished online in the Journal of the American Chem...roaches for these diseases. , The molecules ca...(ARM-H) and "antibody-recruiting molecule targetin...
(Date:11/4/2009)...ridors in the cities of Long Beach and Riverside a...ventable childhood asthma, and the true impact of ...s likely been underestimated, according to researc...). , The study, which appears in an online edit...timated that nine percent of all childhood asthma ...
(Date:11/4/2009)... Oklahoma at Norman has received more than $10 mil... as part of the federal stimulus program, bringing...U researchers to $23 million. Thirty-three projec...rom archaeology to weather. , "The university ha... matching areasof scholarly excellence to federal ...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3TransTech Services Partners Inc Shareholders Approve Plan of Liquidation 3B Company To Distribute Amounts in Trust 12971 1TransTech Services Partners Inc Shareholders Approve Plan of Liquidation 3B Company To Distribute Amounts in Trust 12971 2Caraco Pharmaceutical Laboratories Ltd Enters Into Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram 51327 1Caraco Pharmaceutical Laboratories Ltd Enters Into Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram 51327 2Telomeres resemble DNA fragile sites 9204 1Telomeres resemble DNA fragile sites 9204 2
...ting Initiative (GVFI), a nonprofit research initi...ved $11 million dollars from Google.org and The Sk...illion dollars from each organization, represents ..., an organization whose mission it is to prevent f...ed, brings together fieldwork in disease hotspots ...
...elp Meet Federal Meal Reimbursement ...TOWN, Pa., Oct. 20 ,BIO-key International, Inc. (O... biometric identification and wireless public safe...ng biometric finger scanning ID,for schools, annou...ometric,finger scanning identity solution that qui...
...predominant form of mercury found in the blood of ...be more damaging to seals than has previously been...pen access journal Environmental Health shows th... immune system. Similar results were also found fo...to occur as a result of man-made pollution and nat...
Other Biology News:Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system 2identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 2identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 3identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide 4
...erials for 15-20 enhancements when used as directe...ement System is designed to amplify the desired si... tool for evaluating proteins with low expression....treat membrane prior to blocking the membrane; 1x ...
ReBlot™ Plus Kit from Upstate
EGTA, Molecular Biology Grade from Research Organics, Inc.
...ium esters have moderate chemiluminescence efficie...l understood. They have the added benefit that the...bute little to the background signal. This benefit...ivity immunoassay applications. These compounds ca...
Biology Products: